Navigation Links
FDA Reviewing Potential Anti-Arrhythmic Claims for Ranexa(R)
Date:12/7/2007

PALO ALTO, Calif., Dec. 7 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that the U.S. Food and Drug Administration (FDA) has notified the Company that it will evaluate the approval of potential anti-arrhythmic claims for Ranexa(R) (ranolazine extended-release tablets) as part of its ongoing review of the Company's supplemental new drug application (sNDA).

This follows the FDA's acceptance of an sNDA seeking expansion to the approved product labeling for Ranexa to include a first line angina indication and a significant reduction in cautionary language as well as a separate NDA for a potential labeling change to add reduction of hemoglobin A1c (HbA1c) in coronary artery disease patients with diabetes. The two sNDAs are being reviewed by the FDA Division of Cardiovascular and Renal Products and the NDA is being reviewed by the FDA Division of Metabolism and Endocrinology Products.

The Prescription Drug User Fee Act (PDUFA) action date for the sNDAs and the NDA is July 27, 2008. The FDA has requested, and CV Therapeutics has paid three separate user fees to support the review of both sNDAs and the NDA.

"We anticipate receiving approval for first line angina use, which would significantly expand the patient population eligible to receive Ranexa, and we are very pleased that the FDA also is now evaluating separate potential anti- arrhythmic and HbA1c reduction claims for Ranexa on the same timeline," said Louis G. Lange, CV Therapeutics chairman and chief executive officer.

In September 2007, data published in Circulation and presented at the European Society of Cardiology Congress 2007 in Vienna, Austria showed that Ranexa reduced ventricular arrhythmias in pati
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. InstaCare Corp. Reviewing M&A Plans
2. Thomson Scientific Publishes its Third Quarter Issue of the Ones to Watch Reviewing the Most Promising Drugs in the Pharmaceutical Pipeline
3. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
4. UCLA study identifies designer estrogen as potential MS drug
5. Office-Based Medical Treatment and Internet Resources Are Potential Solution to Rising Painkiller Misuse Among Teens, Young Adults
6. Common abdominal pain may be due to a potentially treatable newly recognized inflammatory reaction
7. Potential new approach to treat cognitive impairments in schizophrenia
8. Nosespray vaccine using aloe vera has exciting potential, researcher says
9. Network approach identifies potential breast cancer susceptibility gene
10. Liver fibrosis will be treated by a potential target
11. Researchers study potential health benefits of natural chemicals in muscadine grape seeds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Gerontological Society of America (GSA) ... field of aging has chosen Madonna Harrington ... PhD, of the University of Luxembourg; and Philipp ... The London School of Economics and Political Science ... Innovative Publication Awards. , These distinguished honors recognize ...
(Date:8/1/2014)... 2014 Lifeinsurancenomedicalexam.info has released a ... for clients who have high cholesterol levels. , ... and qualify for no medical exam life insurance. These ... background medical check-ups. , Since there are no medical ... will qualify in just a few minutes. However, this ...
(Date:8/1/2014)... August 01, 2014 Home Care Assistance ... seniors, is honored to be recognized as a 2014 Best ... given to home care providers who rank in the top ... on monthly satisfaction interviews conducted by Home Care Pulse. , ... home care businesses, the best of the best!” says Home ...
(Date:8/1/2014)... aesthetic injectable procedures have grown in popularity as more ... As Botulinum toxin generally known as BOTOX ... health professionals have emerged to perform procedures utilizing this ... Spinelli, MD from the Division of Plastic Surgery Presbyterian ... from Columbia University in New York have assessed the ...
(Date:8/1/2014)... CapsCanada, a leading provider of ... new K-CAPS® (HPMC capsules) manufacturing facility in Lakeshore, ... last year while experiencing growing global demand for ... “KCAPS® are currently sold in more than 60 ... to other HPMC capsules, K-CAPS® have exceptional appearance ...
Breaking Medicine News(10 mins):Health News:Harrington Meyer, Leist, Hessel, Avendano to receive GSA's 2014 Kalish awards 2Health News:No Exam Life Insurance - Coverage for Clients Who Have High Cholesterol 2Health News:Cincinnati Senior Care Company Receives 2014 Best of Home Care® Employer of Choice Award 2Health News:Plastic surgeons or nurses: Who are the better injectors? 2
... focused on the use of cholesterol-lowering drugs also ... and C-reactive protein levels. C-reactive protein is a ... inflammation in the arteries. One study shows C-reactive ... cardiovascular risk.,Researchers focused on whether the lower low-density ...
... heart's own can, such as raising the heart rate when ... hill but researchers say a pacemaker created by // stem ... shown that genetically engineered heart cells from human embryonic stem ... to a new study. Researchers injected clusters of human beating ...
... body’s immune system and help protect the body against ... shows promising treatment for acute myelogenous leukemia // ... from a patient’s family member. Researchers say this ... cancer of the bone marrow that has become resistant ...
... unexpected structural differences in the brains of cocaine addicts. ... brain structure // of 27 cocaine addicts to that ... ,Results showed the amygdala -- a key structure in ... brain's reward processing system -- is smaller in cocaine ...
... more important factor associated with childhood allergies and asthma than ... to a new study . // ,The study ... a sample of their cord blood serum taken at birth ... showing a sensitization to certain allergens.The children were assessed at ...
... Epilepsy is a disorder caused by abnormal surges in the ... is found to affect more than 2 million people worldwide. ... by just taking medications. // ,Researchers now say that ... effective surgery is compared to drug therapy when treating those ...
Cached Medicine News:
(Date:8/1/2014)... Mass. , Aug. 1, 2014  NxStage Medical, Inc. ... dialysis products, today announced that Jeffrey H. Burbank , ... Officer, will present at the 34 th Annual Canaccord ... Boston, MA , on Wednesday, August 13 th ... will be made available at http://ir.nxstage.com/ .  ...
(Date:8/1/2014)... 2014 Arena Pharmaceuticals, Inc. (NASDAQ: ... and reported financial results for the second quarter ... have continued to see encouraging advancements in the ... increase in estimated total prescriptions and estimated total ... Jack Lief, Arena,s President and Chief Executive Officer. ...
(Date:7/31/2014)... 2014 STAAR Surgical Company (NASDAQ: ... implantable lenses and delivery systems for the eye today ... 2014 of $20.0 million, a 10% increase over $18.2 ... a constant currency basis, revenues grew 11% during the ... of 2013.  The effect of foreign currency exchange reduced ...
Breaking Medicine Technology:NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 4Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 6Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 7Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 8Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 9Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 10Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25
... NEW YORK, June 13, 2011 Reportlinker.com ... is available in its catalogue: ... in Key SADC Countries ... aim of this research service is to ...
... 2011 Science, public health, and regulatory highlights from ... this document is designed for credentialed journalists. Release dates and ... (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... or enforcement actions due to legal limitations. ...
Cached Medicine Technology:Reportlinker Adds Distributor Analysis of the Pharmaceutical Industry in Key SADC Countries 2Reportlinker Adds Distributor Analysis of the Pharmaceutical Industry in Key SADC Countries 3
The AIA-600 II has become the new standard in benchtop immunoassay analyzers....
... The ACON PSA Semi-Quantitative Prostate Specific ... Blood/Serum/Plasma) are lateral flow tests in strip ... of Prostate Specific Antigen (PSA). The tests ... ng/mL cut-off values, and all come with ...
... Assess Functional Vision, Quality of Vision ... controls both target illumination and glare ... testing results. Day/Night testing with/without glare ... Standards and all ANSI standards. All ...
... is Recognized as a Valuable Tool ... by Early Eye Disease. Near Test ... 7 in (12.7cm x 17.78cm) Can ... Refractor,Distance Test F.A.C.T. 201: Size ...
Medicine Products: